Akero Therapeutics, Inc. (AKRO)

NASDAQ: AKRO · IEX Real-Time Price · USD
45.86
-0.06 (-0.13%)
Sep 25, 2023, 10:05 AM EDT - Market open
-0.13%
Market Cap 2.55B
Revenue (ttm) n/a
Net Income (ttm) -115.52M
Shares Out 55.60M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,913
Open 45.37
Previous Close 45.92
Day's Range 45.01 - 45.90
52-Week Range 25.97 - 58.38
Beta -0.93
Analysts Strong Buy
Price Target 63.38 (+38.2%)
Earnings Date Nov 3, 2023

About AKRO

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatmen... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 44
Stock Exchange NASDAQ
Ticker Symbol AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $63.38, which is an increase of 38.20% from the latest price.

Price Target
$63.38
(38.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

25 days ago - GlobeNewsWire

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

4 weeks ago - GlobeNewsWire

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

-- Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, repor...

6 weeks ago - GlobeNewsWire

Weight-loss drugs in development aim to replace injections with pills

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in ...

Other symbols: ETNBLLYMDGLNVOPFEVRTX
3 months ago - Market Watch

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology

Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses Data show changes in non-invasive tests ...

3 months ago - GlobeNewsWire

3 Mid Caps You Haven't Heard Of But Need To Know About

There have been plenty of headlines in recent weeks regarding the influence a few tech titans are having on the broader market rally that's underway, with some voices suggesting the S&P 500 would actu...

Other symbols: AIJOBY
3 months ago - MarketBeat

Akero says NASH drug shown to reduce liver fat by 65% in some patients

Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic st...

3 months ago - Reuters

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone

4 months ago - GlobeNewsWire

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data

4 months ago - GlobeNewsWire

Akero Therapeutics to Present at the Jefferies Healthcare Conference

SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease mar...

4 months ago - GlobeNewsWire

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

4 months ago - GlobeNewsWire

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter ...

4 months ago - GlobeNewsWire

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

The planned Phase 3 program consists of three trials, SYNCHRONY Histology , SYNCHRONY Real-World , and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NAS...

6 months ago - GlobeNewsWire

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

6 months ago - GlobeNewsWire

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

9 months ago - GlobeNewsWire

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

9 months ago - GlobeNewsWire

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023

9 months ago - GlobeNewsWire

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

Designation based on Akero's Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks Designat...

10 months ago - GlobeNewsWire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

11 months ago - GlobeNewsWire

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022

Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liv...

11 months ago - GlobeNewsWire

Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

11 months ago - GlobeNewsWire

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

1 year ago - GlobeNewsWire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

1 year ago - GlobeNewsWire

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

1 year ago - GlobeNewsWire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

1 year ago - GlobeNewsWire